ArticleBMC cancer2026
Machine learning-based prediction of long-term prognosis in cervical adenocarcinoma: a retrospective cohort study.
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundCervical adenocarcinoma continues to pose a major global health challenge, highlighting the importance of accurate survival prediction and timely clinical intervention. This study developed machine learning (ML)–based models that integrate key demographic and clinical variables to enable accurate and non-invasive identification of patients at high prognostic risk.
methodsThis retrospective study enrolled 192 patients with cervical adenocarcinoma from the First Affiliated Hospital of Gannan Medical University and included an external testing cohort of 144 patients from Ganzhou People’s Hospital. Ten ML algorithms—logistic regression, multilayer perceptron, extreme gradient boosting, bootstrap aggregating, decision tree, K-nearest neighbors, light gradient boosting machine, naive Bayes, and random forest (RF)—were used to construct prognostic risk prediction models. The primary endpoint was overall survival, with model performance evaluated at the 5-year time point, whereas time to pelvic recurrence and time to distant metastasis were assessed with a focus on a 2-year time horizon.
resultsThe RF model demonstrated robust predictive performance, achieving F1 scores of 0.897 in the training cohort and 0.846 in the internal testing cohort, with corresponding areas under the receiver operating characteristic curve of 0.836 and 0.880, respectively. External testing in an independent cohort further confirmed the robustness and generalizability of the models, with the RF model achieving the best performance (AUC = 0.779). A higher FIGO stage, larger tumor diameter, and LNM were strongly associated with worse survival outcomes, whereas lower RBC counts and older age also contributed to elevated prognostic risk. Model-derived risk stratification revealed distinct recurrence and metastasis patterns, with the high-risk group showing significantly higher cumulative incidences of pelvic recurrence and distant metastasis compared with the low-risk group (P < 0.001).
conclusionOur ML–based model accurately identified high-risk patients with poor prognostic outcomes, providing a clinically practical tool to support individualized prognostic assessment and treatment planning for cervical adenocarcinoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.